Stockscreener 앱 받기
61.11
10.49%
5.80
시장 영업 전:
61.96
0.85
+1.39%
전일 마감가:
$55.31
열려 있는:
$56.33
하루 거래량:
1.09M
Relative Volume:
1.23
시가총액:
$6.40B
수익:
$628.56M
순이익/손실:
$141.82M
주가수익비율:
48.50
EPS:
1.26
순현금흐름:
$142.60M
1주 성능:
+18.29%
1개월 성능:
+18.89%
6개월 성능:
+80.37%
1년 성능:
+150.25%
1일 변동 폭
$55.90
$61.24
1주일 범위
$52.45
$61.24
52주 변동 폭
$20.84
$62.22
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
61.11 | 6.40B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
Cushing's Syndrome Market Expected to Hit US$ 291.1 million - openPR
Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT) - Insider Monkey
Ovarian Cancer Drugs Market Analysis: Segments, Drivers, - openPR
Here's What Could Help Corcept (CORT) Maintain Its Recent Price Strength - MSN
Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years? - Yahoo Finance
Hennion & Walsh Asset Management Inc. Trims Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Burney Co. Increases Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells $111,188.00 in Stock - MarketBeat
Corcept Therapeutics director Daniel Swisher sells $111,188 in stock By Investing.com - Investing.com Canada
Corcept Submits Application for Another Cushing's Syndrome Drug - MSN
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
JPMorgan Chase & Co. Has $11.71 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Cushings Syndrome Market Is Booming Worldwide 2024-2031 | Corcept Therapeutics Inc., HRA Pharma - EIN News
Range Financial Group LLC Buys New Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased Guidance - Yahoo Finance
Corcept Therapeutics officer sells shares for $251,950 - Investing.com India
Corcept Therapeutics officer sells shares for $251,950 By Investing.com - Investing.com Australia
Sean Maduck Sells 20,000 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock - MarketBeat
Corcept Therapeutics' chief business officer sells shares worth $555,551 By Investing.com - Investing.com Nigeria
Corcept Therapeutics' chief business officer sells shares worth $555,551 - Investing.com
Corcept Therapeutics president sells $1 million in stock By Investing.com - Investing.com Canada
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $65.25 Consensus PT from Analysts - Defense World
Corcept asks FDA to OK relacorilant for Cushing’s syndrome - Cushing's Disease News
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Target Price at $65.25 - MarketBeat
Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors - Simply Wall St
Corcept files NDA for new Cushing's syndrome drug By Investing.com - Investing.com Canada
Corcept Therapeutics Submits New Drug Application for Cushing's Sydrome Treatment - MarketWatch
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism - Business Wire
Corcept Therapeutics Submits FDA Application for Breakthrough Cushing's Syndrome Treatment Relacorilant - StockTitan
Principal Financial Group Inc. Lowers Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
MML Investors Services LLC Invests $317,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025? - Yahoo Finance
10 Stocks That Will Make You Rich In 2025 - Insider Monkey
Hypercortisolism research fuels Corcept’s DTC awareness campaign - MM+M Online
What is Zacks Research's Forecast for CORT FY2025 Earnings? - MarketBeat
Abortion Drugs Market Growth in Future Scope 2024-2031 | Corcept - openPR
Zacks Research Issues Negative Forecast for CORT Earnings - MarketBeat
Geode Capital Management LLC Grows Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Wellington Management Group LLP Trims Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
World Investment Advisors LLC Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept’s dazucorilant fails to slow ALS progression in clinical trial - ALS News Today
Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial - Yahoo Finance
Corcept Therapeutics Incorporated (NASDAQ:CORT) Short Interest Down 7.0% in November - MarketBeat
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism - BioSpace
Relacorilant shows promise in long-term hypercortisolism study - Investing.com
Corcept's Phase 3 Study Shows Breakthrough Blood Pressure Results for Relacorilant in Long-term Treatment - StockTitan
Stifel Financial Corp Buys 20,546 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Shares Rise More Than 60% in Three Months: Here's Why - MSN
State Street Corp Has $162.87 Million Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study - MSN
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):